Quintiles Transitional Holdings (Q) Receives Price Target

Quintiles Transitional Holdings (Q) : 10 investment research analysts covering Quintiles Transitional Holdings (Q) have an average price target of $81.4 for the near short term. The highest target price given by the Brokerage Firm to the stock is $88 and the lowest target is $73 for the short term. Analysts expect the variance to be within $4.79 of the average price.

Quintiles Transitional Holdings (Q) : The consensus on Quintiles Transitional Holdings (Q) based on 12 analyst recommendation on the company stock is 1.54, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 8 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future. 3 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.


Also, Citigroup maintains its rating on Quintiles Transitional Holdings (NYSE:Q). The global brokerage major raises the current price target from $72 per share to $75 per share. Analysts at the Citigroup have a current rating of Neutral on the shares. The rating by the firm was issued on July 28, 2016.

Quintiles Transitional Holdings (NYSE:Q): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $77.46 and $77.06 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $77.54. The buying momentum continued till the end and the stock did not give up its gains. It closed at $77.42, notching a gain of 0.16% for the day. The total traded volume was 720,025 . The stock had closed at $77.30 on the previous day.

Quintiles Transnational Holdings Inc. is a biopharmaceutical services company. The Company is a provider of biopharmaceutical development services and commercial outsourcing services. The Company is engaged in the development and commercialization of pharmaceutical therapies. It also offers therapeutic, scientific and analytical services to its biopharmaceutical and other healthcare customers. The Company offers its services through two segments: Product Development and Integrated Healthcare Services. Its product development segment is a contract research organization (CRO) and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. Its Integrated Healthcare Services segment provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services, such as phase research, market access and consulting, and health information analytics and technology consulting.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.